Gene therapy for deafness: researchers track long-term safety and hearing gains
NCT ID NCT06696456
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 people who previously received a gene therapy (AAVAnc80-hOTOF) for hearing loss caused by otoferlin gene mutations. Researchers will monitor safety over the long term, checking for late side effects, and measure hearing improvements using brain response tests. The goal is to ensure the treatment remains safe and effective over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTOFERLIN GENE-MEDIATED HEARING LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146, United States
-
Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona, 08950, Spain
-
National Taiwan University Hospital
Taipei, Taiwan, (R.O.C), 100, Taiwan
-
University of Iowa
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.